The reaction of the skin and its appendages in rheumatoid arthritis patients using subcutaneous methotrexate: A description of three cases
https://doi.org/10.14412/1995-4484-2016-478-481
Abstract
The paper reports the development of the adverse events of the skin and its appendages due to subcutaneous methotrexate, which serve as a manifestation of its toxicity in patients with rheumatoid arthritis. It discusses the possible mechanisms of their occurrence, although both clinical presentations and histological changes are not specific.
About the Authors
Yu. V. Muravyev
V.A. Nasonova Research Institute of Rheumatology, Moscow
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
G. I. Gridneva
V.A. Nasonova Research Institute of Rheumatology, Moscow
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
S. G. Radenska-Lopovok
V.A. Nasonova Research Institute of Rheumatology, Moscow
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
N. I. Kharitonova
Federal Medical Center, Russian Federal Property Management Agency, Moscow
Russian Federation
31, Kalanchevskaya Street, Moscow 107078
Russian Federation
31, Kalanchevskaya Street, Moscow 107078
References
1. Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol. 2009;146(5):489-503. doi: 10.1111/j.1365-2141.2009.07765.x
2. Frei E, Blum RH, Pitman SW, et al. High-dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med. 1980;68(3):370-6. doi: 10.1016/0002- 9343(80)90105-9
3. Del Pozo J, Martinez W, Garcia-Silva J, et al. Cutaneous ulceration as a sign of methotrexate toxicity. Eur J Dermatol. 2001;11(5):450-2.
4. Pearce HP, Wilson BB. Erosion of psoriatic plaques: an early sign of methotrexate toxicity. J Am Acad Dermatol. 1996;35 (5 Pt 2):835-8. doi: 10.1016/S0190-9622(96)90097-3
5. Yelamos O, Catala A, Vilarrasa E, et al. Acute severe methotrexate toxicity in patients with psoriasis: a case series and discussion. Dermatology. 2014;229(4):306-9. doi: 10.1159/000366501
6. Jindal N, Arora K, Jindal P, et al. Inflamed psoriatic plaques: drug toxicity or disease exacerbation? Ind J Pharmacol. 2013;45(4):410-1. doi: 10.4103/0253-7613.115001
7. Sanz-Sanchez T, Romero-Mate A, Tardхo JC, et al. Acantholytic dermatosis in psoriaticpatient with methotrexate toxicity. J Eur Acad Dermatol Venereol. 2008;22(10):1236-7. doi: 10.1111/j.1468- 3083.2007.02551.x
8. Gaigl Z, Seitz CS, Brocker EB, Trautmann A. Methotrexateinduced toxic epidermal necrolysis-like skin toxicity. Eur J Dermatol. 2007;17(2):168-9.
9. Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31(4):645-8.
10. Braun J, Kä stner P, Flaxenberg P, et al.; MC-MTX.6/RH Study Group. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58(1):73-81. doi: 10.1002/art.23144
11. Каратеев ДЕ, Лучихина ЕЛ, Муравьев ЮВ и др. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА). Научно-практическая ревматология. 2013;51(2):117-25 [Karateev DE, Luchikhina EL, Muravyev YuV, et al. The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(2):117-25 (In Russ.)]. doi: 10.14412/1995-4484-2013-637
12. Delyon J, Ortonne N, Benayoun E, et al. Low-dose methotrexateinduced skin toxicity: Keratinocyte dystrophy as a histologic marker. J Am Acad Dermatol. 2015;73(3):484-90. doi: 10.1016/j.jaad.2015.06.015
13. Ulrich CM, Yasui Y, Storb R, et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood. 2001;98:231-4. doi: 10.1182/blood.V98.1.231
14. Toffoli G, Veronesi A, Boiocchi M, et al. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide,methotrexate and luorouracil (CMF). Ann Oncol. 2000;11:373-4. doi: 10.1023/A:1008337900349
15. Choe JY, Lee H, Jung HY, et al. Methylenetetrahydrofolate reductase polymorphisms, C677T and A1298C are associated with methotrexate-related toxicities in Korean patients with rheumatoid arthritis. Rheumatol Int. 2012;32:1837-42. doi: 10.1007/s00296-011-1989-5
Review
For citations:
Muravyev Yu.V., Gridneva G.I., Radenska-Lopovok S.G., Kharitonova N.I. The reaction of the skin and its appendages in rheumatoid arthritis patients using subcutaneous methotrexate: A description of three cases. Rheumatology Science and Practice. 2016;54(4):478-481. (In Russ.) https://doi.org/10.14412/1995-4484-2016-478-481
Views:
1328
Email this article 